Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(169 produtos)
- Bcr-Abl(122 produtos)
- EGFR(596 produtos)
- FAK(73 produtos)
- FLT(87 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(183 produtos)
- JAK(245 produtos)
- PDGFR(130 produtos)
- RAAS(93 produtos)
- Src(82 produtos)
- Syk(38 produtos)
- Trombina(61 produtos)
- VDA(2 produtos)
- VEGFR(257 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2381 produtos para "Angiogénese".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFórmula:C23H26N6O5SPureza:98%Cor e Forma:SolidPeso molecular:498.55MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFórmula:C29H29N7OPureza:98%Cor e Forma:SolidPeso molecular:491.59ATWLPPR Peptide
CAS:ATWLPPR Peptide is a biologically active peptide functioning as a specific antagonist to VEGFR2/KDR.Fórmula:C40H61N11O9Peso molecular:839.98hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Fórmula:C22H23FN6O5SPureza:98%Cor e Forma:SolidPeso molecular:502.52ALK5-IN-84
ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pKi value of 9.35 for hALK5. Administered via inhalation, ALK5-IN-84 exhibits significant ALK5 inhibitory activity. This compound holds potential for research in developing inhalable ALK5 inhibitors.Fórmula:C20H20ClFN6OPeso molecular:414.86FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Fórmula:C24H22N6O2Cor e Forma:SolidPeso molecular:426.47EGFR-IN-120
EGFR-IN-120 (Compound 11eg) is an orally effective EGFR inhibitor. It exhibits potency against the EGFR L858R/T790M/C797S mutant with an IC50 of 0.053 μM, and displays weaker activity against EGFRWT, with an IC50 of 1.05 μM. EGFR-IN-120 inhibits the phosphorylation of EGFR as well as key downstream effectors including STAT3, AKT, and Erk. This compound induces cell cycle arrest and apoptosis in cells harboring the EGFR mutation. Additionally, EGFR-IN-120 inhibits the proliferation of NSCLC cells containing the EGFR L858R/T790M/C797S mutation, with an IC50 value of 0.052 μM.Cor e Forma:Odour SolidMS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5LDN 193688
CAS:LDN 193688 is a BMP kinase inhibitor preferential for the ALK2 site, acting by binding to the ALK site,progressive osseous fibrodysplasia.Fórmula:C22H16N4OPureza:99.48%Cor e Forma:SolidPeso molecular:352.39M4K2234
CAS:M4K2234 (26b) inhibits ALK2/ALK5 (IC50: 5/2144 nM), used as a probe for ALK1/2 kinases in cancer research.Fórmula:C27H31FN4O2Pureza:99.99%Cor e Forma:White SolidPeso molecular:462.56Arginyl-Glutamine
CAS:Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects neonatal mice from hyperoxia-induced lung injury, lowering VEGF levels.Fórmula:C11H22N6O4Pureza:95.2%Cor e Forma:White SolidPeso molecular:302.33PROTAC FAK degrader 1
CAS:PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).Fórmula:C47H56F3N9O8S2Pureza:98%Cor e Forma:SolidPeso molecular:996.13EGFR T790M/L858R-IN-2
EGFRT790M/L858R-IN-2: selective inhibitor, IC50: 3.5 nM (mutant), 1290 nM (WT); reduces p-EGFR/AKT/ERK1/2, triggers apoptosis, G1 arrest, anti-cancer.Fórmula:C28H28FN7OCor e Forma:SolidPeso molecular:497.57Bevasiranib
CAS:Bevasiranib is a siRNA targeting VEGF production, key in choroidal neo-vascularization and wet AMD.Cor e Forma:SolidAntitumor agent-123
Antitumor agent-123 (Compound 4d) effectively inhibits various kinase targets with anticancer properties, including JAK2, JAK3, HDAC1, and HDAC6, with IC50 values of 34.6 μM for JAK2 and 2.6 μM for JAK3. In solid tumor models, Antitumor agent-123 demonstrates moderate activity.Fórmula:C19H14ClFN6O2Cor e Forma:SolidPeso molecular:412.08508MS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Fórmula:C60H76ClFN10O8SPureza:98%Cor e Forma:SolidPeso molecular:1151.82BTK degrader-1
CAS:BTK degrader-1 (compound 1), a bifunctional degrader of Bruton's tyrosine kinase (BTK), demonstrates the capability to be conjugated with CD79b and exhibits anti-tumor effects [1].Fórmula:C52H54F2N8O6Cor e Forma:SolidPeso molecular:925.03JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.161Abl Cytosolic Substrate
CAS:Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Fórmula:C64H101N15O16Pureza:98%Cor e Forma:SolidPeso molecular:1336.58SJ988497
CAS:SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74
